NEW DELHI: National Pharmaceutical Pricing Authority (NPPA) has allowed pharma companies to marginally increase prices of scheduled formulations included in National List of Essential Medicines (NLEM) from April 1. The drugs include commonly used painkillers, antibiotics, diabetes medications, and anti-rabies immunoglobulin, among others, reports Durgesh Nandan Jha.
Each unit of anti-rabies immunoglobulin (injection 150 IU/ml) will now be available for maximum Rs 3,454.Ceiling price of anti-tetanus immunoglobulin was fixed at Rs 1,383.6. A unit of Amikacin (injection 250 mg/ml) will cost maximum Rs 54.2, as per NPPA order.
Quantum of increase in prices of scheduled formulation included in NLEM is based on change in Wholesale Price Index of formulation for the preceding year, as decided in Drug (Pricing Control) Order 2013. Unlike the previous year, when WPI change was in excess of 10%, this year the movement is significantly low leading to a marginal increase in prices of scheduled formulations.
Indian Pharmaceutical Alliance secretary general Sudarshan Jain said the price increase is per norms laid down by govt.
Each unit of anti-rabies immunoglobulin (injection 150 IU/ml) will now be available for maximum Rs 3,454.Ceiling price of anti-tetanus immunoglobulin was fixed at Rs 1,383.6. A unit of Amikacin (injection 250 mg/ml) will cost maximum Rs 54.2, as per NPPA order.
Quantum of increase in prices of scheduled formulation included in NLEM is based on change in Wholesale Price Index of formulation for the preceding year, as decided in Drug (Pricing Control) Order 2013. Unlike the previous year, when WPI change was in excess of 10%, this year the movement is significantly low leading to a marginal increase in prices of scheduled formulations.
Indian Pharmaceutical Alliance secretary general Sudarshan Jain said the price increase is per norms laid down by govt.